The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy
2012 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 92, no 1, 112-117 p.Article in journal (Refereed) Published
Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.
Place, publisher, year, edition, pages
2012. Vol. 92, no 1, 112-117 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-177563DOI: 10.1038/clpt.2012.57ISI: 000305589800019OAI: oai:DiVA.org:uu-177563DiVA: diva2:541282